Skip to content

Clinical trials

Phase 4 Papillomavirus Infections trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Papillomavirus Infections Phase: Phase 4 Clear all

33 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20092
20104
20141
20171
20181
20206
20212
20227
20234
20241
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Unknown status7
Recruiting6
Active, not recruiting5
Enrolling by invitation1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Washington3
GlaxoSmithKline2
National Cancer Institute (NCI)2
AGUNCO Obstetrics and Gynecology Centre1
Boston Medical Center1
Catalysis SL1
Centre Hospitalier Universitaire de la Réunion1
Chinese Academy of Medical Sciences1
Columbia University1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Papillomavirus Infections33
Uterine Cervical Neoplasms7
Acquired Immunodeficiency Syndrome2
Uterine Cervical Dysplasia2
Atypical Squamous Cells of the Cervix1
HIV Infections1
Infections1
Persistent Infection1
Squamous Intraepithelial Lesions1
Squamous Intraepithelial Lesions of the Cervix1

Trials

Showing 76 to 33 of 33. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.